Compare · IKNA vs MRNA
IKNA vs MRNA
Side-by-side comparison of Ikena Oncology Inc. (IKNA) and Moderna Inc. (MRNA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both IKNA and MRNA operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- MRNA is the larger of the two at $24.53B, about 72.4x IKNA ($339.0M).
- Over the past year, IKNA is up 11.8% and MRNA is up 99.5% - MRNA leads by 87.7 points.
- MRNA has hit the wire 10 times in the past 4 weeks while IKNA has been quiet.
- MRNA has more recent analyst coverage (25 ratings vs 5 for IKNA).
- Company
- Ikena Oncology Inc.
- Moderna Inc.
- Price
- $1.42+2.90%
- $61.80-2.14%
- Market cap
- $339.0M
- $24.53B
- 1M return
- +11.81%
- +11.57%
- 1Y return
- +11.81%
- +99.48%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- 2018
- News (4w)
- 0
- 10
- Recent ratings
- 5
- 25
Ikena Oncology Inc.
Ikena Oncology, Inc., a targeted oncology company, focuses on developing novel cancer therapies targeting key signaling pathways that drive the formation and spread of cancer. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, a selective AHR antagonist; IK-412, a recombinant human kynurenine-degrading enzyme; and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Moderna Inc.
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, and Bill & Melinda Gates Foundation. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of COVID-19 vaccine; and Catalent Inc., Laboratorios Farmacéuticos Rovi, S.A., Recipharm, and Lonza Group for fill-finish manufacturing of its COVID-19 vaccine candidate, as well as Aldevron, LLC for supporting COVID-19 vaccine and additional programs in company's clinical development pipeline. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Latest IKNA
- Ikena Oncology Inc. filed SEC Form 8-K: Leadership Update, Other Events
- SEC Form 4 filed by Chief Executive Officer Yarema Kristin
- Director Orbimed Advisors Llc was granted 83,611 shares (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13D/A filed by Ikena Oncology Inc.
- Director Bonita David P converted options into 379 shares and bought $2,499,969 worth of shares (83,611 units at $29.90) (SEC Form 4)
- Director Stampacchia Otello converted options into 379 shares and bought $7,999,924 worth of shares (267,556 units at $29.90) (SEC Form 4)
- Chief Financial Officer Marango Jotin was granted 15,776 shares and covered exercise/tax liability with 4,630 shares (SEC Form 4)
- Principal Accounting Officer Butler Erin was granted 3,051 shares (SEC Form 4)
- SEC Form 3 filed by new insider Butler Erin
- SEC Form 3 filed by new insider Yarema Kristin
Latest MRNA
- President Hoge Stephen exercised 53,336 shares at a strike of $19.15 and sold $3,605,514 worth of shares (53,336 units at $67.60) as part of a pre-agreed trading plan (SEC Form 4)
- Moderna Announces First Participant Dosed in Phase 1 Clinical Trial Evaluating Investigational Tumor-Targeted Cancer Antigen Therapy in Solid Tumors
- SEC Form 4 filed by Director Mcdonnell Michael R.
- SEC Form 3 filed by new insider Mcdonnell Michael R.
- Moderna to Report Second Quarter 2026 Financial Results on Friday, July 31, 2026
- Moderna Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Moderna Appoints Michael McDonnell to Board of Directors
- SEC Form 4 filed by Chief Commercial Officer Banque Soria Ester
- Chief Financial Officer Mock James M converted options into 1,452 shares and covered exercise/tax liability with 703 shares, increasing direct ownership by 1% to 66,436 units (SEC Form 4) to satisfy withholding tax
- SEC Form 3 filed by new insider Banque Soria Ester